Endpoint analysis from EMPEROR-Preserved shows that in 5,988 adults with heart failure with LVEF over 40%, the once-daily dose of Jardiance demonstrated a 21% relative risk reduction (3.3% ...
The FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new use, to reduce the risk of renal failure and cardiovascular death in people with chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback